MDS 2020 | Promising advanced tau therapies for movement disorders

Adam Boxer, MD, PhD, UCSF Weill Institute for Neurosciences, San Francisco, CA, discusses the advanced tau therapies that are currently under investigation for movement disorders. The current strategies are active vaccinations, monoclonal antibodies, oligonucleotides and gene therapy, which target the tau protein itself. Prof Boxer briefly discusses the active clinical trials for Alzheimer’s disease and how they show potential for movement disorders. This interview was recorded during an online conference call with The Video Journal of Neurology (VJNeurology).